

CONCLUSION:

The above case study indicates that the TKI-induced BRAF V600E mutation is an acquired resistance mechanism to Osimertinib. Treatment with combination of dabrafenib/trametinib and Osimertinib, thus seems to be effective in lung adenocarcinoma.

REFERENCES:

1. Ribeiro, M.F.S.A., Knebel, F.H., Bettoni, F. et al. Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. *npj Precis. Onc.* 5, 5 (2021). <https://doi.org/10.1038/s41698-021-00149-4>
2. Abdulla, Diana & Scheffler, Matthias & Kobe, Carsten & Persigehl, Thorsten & Schmidt, Matthias & Fassunke, Jana & Merkelbach-Bruse, Sabine & Michels, Sebastian & Nogova, Lucia & Koleczko, Sophia & Fischer, Rieke & Riedel, Richard & Drzezga, Alexander & Büttner, Reinhard & Wolf, Jürgen. (2019). Overcoming acquired osimertinib-resistance in EGFR - mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation. *Journal of Clinical Oncology*. 37. e20682-e20682. 10.1200/JCO.2019.37.15_suppl. e20682.
3. Zofia Piotrowska, Lecia V Sequist, MD, MPH. Tackling the Next Generation of Resistance in EGFR-Mutant Lung Cancer (2017). *Journal of Thoracic Oncology*. <https://doi.org/10.1016/j.jtho.2017.01.018>.
4. Pei Meng, Bart Koopman, Klaas Kok, Arja ter Elst, Ed Schuurin, Léon C. van Kempen, Wim Timens, T. Jeroen N. Hiltermann, Harry J.M. Groen, Anke van den Berg, Anthonie J. van der Wekken. Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation. *Lung Cancer* (2020). <https://doi.org/10.1016/j.jtho.2017.01.018>.
5. http://www.apmggroup.net/innovation/molecular_testing/Colon_Pathways/colon.html
6. Hsu K-H, Ho C-C, Hsia T-C, Tseng J-S, Su K-Y, Wu M-F, et al. (2015) Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan. *PLoS ONE* 10(3): e0120852. <https://doi.org/10.1371/journal.pone.0120852>